550 research outputs found
Serendipity: Decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia
Interruption of the IFNγR/CXCR3 Axis Results in Altered T Cell Trafficking in Vivo and Abrogation of GVHD While Maintaining a Robust GVL Response
Risk for Clostridium difficile infection after allogeneic hematopoietic cell transplant remains elevated in the postengraftment period
BACKGROUND: Clostridium difficile infection (CDI) is a frequent cause of diarrhea among allogeneic hematopoietic cell transplant (HCT) recipients. It is unknown whether risk factors for CDI vary by time posttransplant. METHODS: We performed a 3-year prospective cohort study of CDI in allogeneic HCT recipients. Participants were enrolled during their transplant hospitalizations. Clinical assessments were performed weekly during hospitalizations and for 12 weeks posttransplant, and monthly for 30 months thereafter. Data were collected through patient interviews and chart review, and included CDI diagnosis, demographics, transplant characteristics, medications, infections, and outcomes. CDI cases were included if they occurred within 1 year of HCT and were stratified by time from transplant. Multivariable logistic regression was used to determine risk factors for CDI. RESULTS: One hundred eighty-seven allogeneic HCT recipients were enrolled, including 63 (34%) patients who developed CDI. 38 (60%) CDI cases occurred during the preengraftment period (days 0-30 post-HCT) and 25 (40%) postengraftment (day >30). Lack of any preexisting comorbid disease was significantly associated with lower risk of CDI preengraftment (odds ratio [OR], 0.3; 95% confidence interval [CI], 0.1-0.9). Relapsed underlying disease (OR, 6.7; 95% CI, 1.3-33.1), receipt of any high-risk antimicrobials (OR, 11.8; 95% CI, 2.9-47.8), and graft-versus-host disease (OR, 7.8; 95% CI, 2.0-30.2) were significant independent risk factors for CDI postengraftment. CONCLUSIONS: A large portion of CDI cases occurred during the postengraftment period in allogeneic HCT recipients, suggesting that surveillance for CDI should continue beyond the transplant hospitalization and preengraftment period. Patients with continued high underlying severity of illness were at increased risk of CDI postengraftment
Booster Infusion of T-Cell Depleted, CD34+ Enriched, Donor Cells Results in Sustained Count Recovery for Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation
Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: Long-term follow-up report
A novel conditioning regimen of immune suppression with campath-1H, fludarabine and melphalan in stem cell transplantation for non-malignant disorders
Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: A case-control study
Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: Evaluation of a CDAD severity grading system
- …